Data were included for 79,550 patients treated with intravenous thrombolysis, of whom 11.9% and 88.1% received tenecteplase and alteplase, respectively.

HealthDay News — For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes, according to a study published ...

At the current average wholesale cost of the smaller, commercially available alteplase vial (containing 50 mg), the average cost per milligram of alteplase is $27.50. [27] ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. HealthDay News — The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit. Results show that TNKase was comparable to ...

TNKase is a faster, simpler stroke treatment, given as a single five-second IV bolus, unlike Activase’s 60-minute infusion. Genentech will soon launch a new 25 mg vial to support its AIS ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

Results show that TNKase was comparable to Activase in terms of efficacy and safety. Stroke affects more than 795,000 people ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed ...

TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by a ...

– TNKase® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administration than the approved ...